Diclofenac-associated hepatotoxicity: Analysis of 180 cases reported to the food and drug administration as adverse reactions
Open accessThe DOI matches its Crossref record; 16 of the 16 references it cites were found in a registry or an index.
Abstract
Diclofenac is a nonsteroidal anti-inflammatory drug approved in the United States in 1988 for the treatment of patients with osteoarthritis, rheumatoid arthritis, or ankylosing spondylitis. To characterize the clinical, biochemical, and histological features and possible mechanisms of hepatic injury associated with its use, a retrospective analysis was undertaken of 180 patients whose cases were reported to the Food and Drug Administration from November 1988 through June 1991, as having had possible adverse reactions to diclofenac. Of the reported 180 cases, 79% were female, 71% were 60 years of age or older, and 77% had osteoarthritis. Sixty-seven percent of the cases were detected by symptoms and the remainder by abnormal laboratory tests. Seventy-five percent of the symptomatic patients (90 of 120) were jaundiced. Seven of the 90 icteric patients died. The biochemical pattern of injury was hepatocellular or mixed hepatocellular in 66% of cases. Only 8% had a pattern of cholestatic injury. The remainder, with modestly increased values of both transaminases and alkaline phosphatase, were considered “indeterminate,” i.e., either mild hepatocellular or anicteric “cholestatic” injury. Sections of liver from 21 cases were available for study. Hepatic injury was apparent by 1 month after starting the drug in 24% by 3 months in 63%, and by 6 months in 85% of cases. The latent period in 12% was 6 to 12 months, whereas in 3% it was greater than 12 months. A combination of rash, fever, and eosinophilia, all hallmarks of immunological idiosyncrasy (hypersensitivity), was not reported in any case; additionally, the long latent period in most of the patients led to the inference that the mechanism is probably metabolic idiosyncrasy. The data suggest that diclofenac-related liver injury is particularly likely to involve osteoarthritic females, presenting with jaundice 1 to 6 months after starting diclofenac, with injury that is predominantly hepatocellular and presumably caused by metabolic idiosyncrasy. (Hepatology 1995; 22:820-827.)
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hepatotoxicity: The adverse effects of drugs and other chemicals on the liver
Maddrey, W. C. (2000) · Gastroenterology · doi:10.1016/s0016-5085(00)70192-2 · Cited by 646
Kretzrommel, A., & Boelsterli, U. A. (1993) · Toxicology and Applied Pharmacology · doi:10.1006/taap.1993.1097 · Cited by 171
Diclofenac-Associated Hepatotoxicity
Helfgott, S. M. (1990) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1990.03450200068033 · Cited by 124
Scully, L. J., Clarke, D., & Barr, R. J. (1993) · Digestive Diseases and Sciences · doi:10.1007/bf01316809 · Cited by 119
O’Brien, W. M. (1986) · The American Journal of Medicine · doi:10.1016/0002-9343(86)90084-7 · Cited by 101
Tarazi, E. M., Harter, J. G., Zimmerman, H. J., Ishak, K. G., & Eaton, R. A. (1993) · Gastroenterology · doi:10.1016/0016-5085(93)90428-f · Cited by 92
Self-citationPekelharing, J. M., Hepp, E., Kamerling, J. P., Gerwig, G. J., & Leijnse, B. (1988) · Annals of the Rheumatic Diseases · doi:10.1136/ard.47.2.91 · Cited by 76
Purcell, P. M., Henry, D. A., & Melville, G. (1991) · Gut · doi:10.1136/gut.32.11.1381 · Cited by 76
Hepatotoxicity of nonsteroidal anti-inflammatory drugs.
Rabinovitz, M., & Thiel, D. H. V. (1992) · PubMed · Cited by 70
Hepatic toxicity of nonsteroidal anti-inflammatory drugs.
Lewis, J. H. (1984) · PubMed · Cited by 68
Cited by
Ecotoxicology of human pharmaceuticals
Fent, K., Weston, A. A., & Caminada, D. (2006) · Aquatic Toxicology · doi:10.1016/j.aquatox.2005.09.009 · Cited by 3,223
Lee, W. M. (2003) · New England Journal of Medicine · doi:10.1056/nejmra021844 · Cited by 1,594
Godoy, P., Hewitt, N. J., Albrecht, U., Andersen, M. E., Ansari, N., Bhattacharya, S., Bode, J. G., Bolleyn, J., Borner, C., Böttger, J., et al. (2013) · Archives of Toxicology · doi:10.1007/s00204-013-1078-5 · Cited by 1,280
Andrade, R. J., Chalasani, N., Björnsson, E. S., Suzuki, A., Kullak-Ublick, G. A., Watkins, P. B., Devarbhavi, H., Merz, M., Lucena, M. I., Kaplowitz, N., et al. (2019) · Nature Reviews Disease Primers · doi:10.1038/s41572-019-0105-0 · Cited by 924
Toxic effects of the non-steroidal anti-inflammatory drug diclofenac
Schwaiger, J., Ferling, H., Mallow, U., Wintermayr, H., & Negele, R. D. (2004) · Aquatic Toxicology · doi:10.1016/j.aquatox.2004.03.014 · Cited by 868
Diclofenac-induced liver injury: a paradigm of idiosyncratic drug toxicity
Boelsterli, U. (2003) · Toxicology and Applied Pharmacology · doi:10.1016/s0041-008x(03)00368-5 · Cited by 403
Daly, A. K., Aithal, G. P., Leathart, J. B. S., Swainsbury, R. A., Dang, T. S., & Day, C. P. (2007) · Gastroenterology · doi:10.1053/j.gastro.2006.11.023 · Cited by 348
Chen, M., Borlak, J., & Tong, W. (2013) · Hepatology · doi:10.1002/hep.26208 · Cited by 348
Acute pain: a multifaceted challenge – the role of nimesulide
Kress, H. G., Baltov, A., Basiński, A., Berghea, F., Castellsague, J., Codreanu, C., Copaciu, E., Giamberardino, M. A., Hakl, M., Hrazdira, L., et al. (2016) · Current Medical Research and Opinion · doi:10.1185/03007995.2015.1100986 · Cited by 316
Role of Drug Disposition in Drug Hypersensitivity: A Chemical, Molecular, and Clinical Perspective
Park, B. K., Pirmohamed, M., & Kitteringham, N. R. (1998) · Chemical Research in Toxicology · doi:10.1021/tx980058f · Cited by 267
Idiosyncratic drug-induced liver injury: an overview
Hussaini, S. H., & Farrington, E. A. (2007) · Expert Opinion on Drug Safety · doi:10.1517/14740338.6.6.673 · Cited by 183
Boelsterli, U. A., Zimmerman, H. J., & Kretz-Rommel, A. (1995) · Critical Reviews in Toxicology · doi:10.3109/10408449509089888 · Cited by 180
Self-citationDrug‐induced liver injury in a Swedish University hospital out‐patient hepatology clinic
DE VALLE, M. B., AV KLINTEBERG, V., ALEM, N., OLSSON, R., & BJÖRNSSON, E. (2006) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2006.03117.x · Cited by 179
Baudy, A. R., Otieno, M. A., Hewitt, P., Gan, J., Roth, A., Keller, D., Sura, R., Van Vleet, T. R., & Proctor, W. R. (2020) · Lab on a Chip · doi:10.1039/c9lc00768g · Cited by 150
Yu, K., Geng, X., Chen, M., Zhang, J., Wang, B., Ilic, K., & Tong, W. (2014) · Drug Metabolism and Disposition · doi:10.1124/dmd.113.056267 · Cited by 150
Fulminant drug-induced hepatic failure leading to death or liver transplantation in Sweden
Björnsson, E., Jerlstad, P., Bergqvist, A., & Olsson, R. (2005) · Scandinavian Journal of Gastroenterology · doi:10.1080/00365520510023846 · Cited by 123
Drug-induced liver injury in older people
Lucena, M. I., Sanabria, J., García-Cortes, M., Stephens, C., & Andrade, R. J. (2020) · The Lancet Gastroenterology & Hepatology · doi:10.1016/s2468-1253(20)30006-6 · Cited by 77
Effect of UGT2B7*2 and CYP2C8*4 polymorphisms on diclofenac metabolism
Lazarska, K. E., Dekker, S. J., Vermeulen, N. P. E., & Commandeur, J. N. M. (2018) · Toxicology Letters · doi:10.1016/j.toxlet.2017.11.038 · Cited by 55
What have we learned from animal models of idiosyncratic, drug-induced liver injury?
Roth, R. A., & Ganey, P. E. (2020) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2020.1760246 · Cited by 8
Metadata
- Authors
- Banks, A. T., Zimmerman, H. J., Ishak, K. G., & Harter, J. G.
- Venue
- Hepatology
- Published
- 1995-09
- Volume
- 22
- Issue
- 3
- Pages
- 820-827
- ISSN
- 0270-9139 (ISSN-L)
- OpenAlex
- W1974541930
- Cited by
- 301
- References
- 16
- FWCI
- 6.38
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.